Vyant Bio Balance Sheet Health

Financial Health criteria checks 3/6

Vyant Bio has a total shareholder equity of $4.5M and total debt of $57.0K, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are $6.2M and $1.7M respectively.

Key information

1.3%

Debt to equity ratio

US$57.00k

Debt

Interest coverage ration/a
CashUS$2.80m
EquityUS$4.50m
Total liabilitiesUS$1.73m
Total assetsUS$6.23m

Recent financial health updates

We Think Vyant Bio (NASDAQ:VYNT) Can Afford To Drive Business Growth

Aug 17
We Think Vyant Bio (NASDAQ:VYNT) Can Afford To Drive Business Growth

Recent updates

Vyant Bio GAAP EPS of -$0.20, revenue of $0.17M

Aug 22

Vyant Bio Q2 2022 Earnings Preview

Aug 12

We Think Vyant Bio (NASDAQ:VYNT) Can Afford To Drive Business Growth

Aug 17
We Think Vyant Bio (NASDAQ:VYNT) Can Afford To Drive Business Growth

Financial Position Analysis

Short Term Liabilities: VYNT's short term assets ($3.4M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: VYNT's short term assets ($3.4M) exceed its long term liabilities ($526.0K).


Debt to Equity History and Analysis

Debt Level: VYNT has more cash than its total debt.

Reducing Debt: Insufficient data to determine if VYNT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VYNT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VYNT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 21.4% each year


Discover healthy companies